Featured Publications
Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection
Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan J, Buitrago‐Pocasangre N, Lele N, Asashima H, Racke M, Wilson J, Givens T, Tomayko M, Schulz W, Longbrake E, Hafler D, Halene S, Fan R. Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection. Small Methods 2023, 7: e2300594. PMID: 37312418, PMCID: PMC10592458, DOI: 10.1002/smtd.202300594.Peer-Reviewed Original ResearchConceptsB cell depletion therapyAcute COVID infectionAnti-spike IgGHigh-risk patientsCoronavirus disease-19COVID-19 pathologyDepletion therapyVaccine protectionAntibody responseCOVID infectionHematologic malignanciesImmune protectionDisease-19Healthy donorsMultiple time pointsSerology assaysBlood samplesSoluble markersB cellsImmunization strategiesPatientsFunctional deficiencySerological analysisTime pointsClonotype diversity
2024
Splicing the Difference: Harnessing the complexity of the transcriptome in hematopoiesis
Maul-Newby H, Halene S. Splicing the Difference: Harnessing the complexity of the transcriptome in hematopoiesis. Experimental Hematology 2024, 104655. PMID: 39393608, DOI: 10.1016/j.exphem.2024.104655.Peer-Reviewed Original ResearchAlternative splicingAlternative splicing eventsStem cell maintenanceSplicing factor mutationsHematopoietic stem cell maintenanceExpression of beta-globinField of stem cell researchSplicing eventsSplicing factorsFunctional blood cellsAberrant splicingStudy of hematopoiesisComplex regulationCell maintenanceSplicingCellular differentiationBeta-globinMyelodysplastic syndromeMyeloid malignanciesHematologic malignanciesStem cell researchCell sortingMutationsTranscriptomeAberrant expression
2020
Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms
Taylor J, Mi X, North K, Binder M, Penson A, Lasho T, Knorr K, Haddadin M, Liu B, Pangallo J, Benbarche S, Wiseman D, Tefferi A, Halene S, Liang Y, Patnaik MM, Bradley RK, Abdel-Wahab O. Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms. Blood 2020, 136: 1477-1486. PMID: 32640014, PMCID: PMC7515689, DOI: 10.1182/blood.2020006868.Peer-Reviewed Original ResearchConceptsHematologic malignanciesMyeloid neoplasmsFactor mutationsSplicing factor mutationsRare amino acid substitutionsCommon allelesMyeloid malignanciesPatientsU2AF1 mutationsCommon alterationsMalignancyHigh-frequency mutationsNeoplasmsMolecular effectsSame individual cellsWild-type alleleK700E mutationDistribution of mutationsAmino acid substitutionsMutationsDouble mutationAllele-specific differencesAllelesCyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro
He X, Dou A, Feng S, Roman-Rivera A, Hawkins C, Lawley L, Zhang J, Wunderlich M, Mizukawa B, Halene S, Patel A, Fang J. Cyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro. Experimental Hematology 2020, 86: 21-27.e2. PMID: 32437909, PMCID: PMC7335335, DOI: 10.1016/j.exphem.2020.05.001.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApoptosisCell Line, TumorCyclosporineDNA-Binding ProteinsDrug Resistance, NeoplasmGene Expression Regulation, LeukemicHumansIkaros Transcription FactorLenalidomideLeukemia, Myeloid, AcuteMiceMice, Inbred NODMuscle ProteinsMyelodysplastic SyndromesNeoplasm ProteinsUp-RegulationXenograft Model Antitumor AssaysConceptsAcute myeloid leukemiaMDS/acute myeloid leukemiaMyelodysplastic syndromeT cell activationAML patient-derived xenograft modelsG protein-coupled receptor 68MDS/AML cellsPatient-derived xenograft modelsMDS/AML cell linesDegradation of IKZF1AML cell linesCell linesActivity of CaNBone marrow cellsMDS patientsPrimary bone marrow cellsHematologic malignanciesMyeloid leukemiaAML cellsLenalidomideXenograft modelDrug AdministrationSuppressive effectProsurvival pathwaysMarrow cells